Cancer Free -

Cancer Free Survival

Were systematically treated according to clinical guidelines. Short chemotherapy, which were used during the 1980s, cyclophosphamide, methotrexate and fluorouracil (CMF); in 1990, of the anthracyclines. and then using more anthracycline therapy-taxane chemotherapy. 57 percent of patients received chemotherapy CMF, 27.4% (based on anthracyclines, 45.9%, with or without anthracyclines, 25.1%;) The taxane chemotherapy and 1.6% unknown). Endocrinology 883 patients administered (like hormone release of luteinizing hormone and tamoxifen, 66.9%, 4.5%, tamoxifen tamoxifen followed by aromatase inhibitor, 19.6%; and aromatase inhibitor 8.9 percent). Eighteen patients received adjuvant Trastuzumab. Patients were followed every 6 months during the first 4 years and every year thereafter. Clinicopathologic and title graphics review information obtained. The study was conducted by the hospital Universitario Virgen de la Victoria of the Ethics Committee and the Fund for health research of the Ministry of science and innovation of Spain with the title of the study of the distribution of time to recurrence for intrinsic (PI081797)-an approved breast cancer subtypes. The need to obtain informed consent without consent obtained patients which data were included in this study, except in cases where the patient was dead, in this case, mentioned ethics committees. ]. These data were confirmed by the same group in a deeper, more than two times more than public coffers contain annotations of cancer microarray data. Having solved on the basis of our future research in a database of patients have been added. To identify the steps recorded III from January 1982 to December 2008, the breast cancer patients was conducted a search filtered. We identified 3,329 patients with stage I-III breast cancer. Almost 50% (n = 1652) were consistent with other centres; As a result, there are no tumor samples were available. 135 patients were for various reasons and other patients 1542, representative samples of the tumor in 293 cases (19%) were excluded patients were finally 1.249 method in the study (figure. Are determined, intrinsic subtypes of breast cancer cancer with four to six panels immunohistochemical indicators and dissemination, assessed through the use of Ki-67 in a cohort of patients collected prospectively large and homogeneous. Our main conclusions are that any inherent sub-type demonstrates a recurrence pattern and a deployment method in the development of early recurrence of key role. These results are directly on clinical approaches of adjuvant treatment and follow-up schedules for the surveillance, suggesting that the two should be different according to the intrinsic subtype. Further understanding of different clinical relapse again organic mode can learn about management and development of the cause of breast cancer. Age, tumor size, histologic grade, lymph node status, local therapy, administration of chemotherapy, hormonal adjuvant and intrinsic biomarkers, defined subtype with four or six variables analyzed included. The goal was the breast cancer-surviving (BCF), defined as the operating time up to regional or local repeat at a distance, a second contralateral tumour or breast cancer deaths, what happened before. Patients had no relapse or were censored that lost during the follow-up to the last follow-up visit. Patients who have died, weren't that breasts as a result of any cause at the time of death is censored. All statistical analyses were performed with the software version 2.14.0 r testing has made it possible to compare the distribution of basic characteristics between subgroups. Actuarial survival was using the Kaplan-Meier method and the differences between the mantel, Kan-ware and Peto Peto test were evaluated. The relationship between the various factors of the CBF and forecast scored with a proportional hazards regression Cox. Just for information for all covariates in the analysis were included (n = 1, 215). A selection of variables was made with the help of the selection process and step by step (the level of importance of the entry and residence of a variable in the model was P < 0.05). Among candidates of various models of Cox, used to analyse the preferred data model were with information policy below. ], including patients treated only with surgery and surgery, as well as several adjuvant chemotherapy-treated patients did this solidity of repeat structure. The path of proliferation plays a key role in the development of early recurrence after breast cancer surgery surgery, regardless of the intrinsic subtype involved. This conclusion is reinforced by the fact that the data from another statistical approach to survive the analysis were obtained. Our results need to be confirmed in large series of patients treated with adjuvant systemic therapy treatments present; Knowledge transfer regarding temporal trends of repetition in the development and design of future clinical studies in the Administration could be seen but when set to sync or treatment that would be a more effective management tool. In addition, our data can some recommendations that have a link with the patient monitoring. ] found that genes, the more intrinsic differ subtypes (A luminal, luminal B, of the human epidermal growth factor 2 (HER2)-enriched, baseline and normal-) were the diffusion group. In this sense, a meta-analysis of publicly available data on breast cancer revealed gene expression, published, including some prognostic signatures that over 70% of the genes that were related to the survival of the patient in relation to the distribution path were associated while 26% 2% for the ERBB2 amplification and estrogen receptor (ER). Our work stresses the importance of the way in which the intrinsic spread in early prognosis subtypes of breast cancer through analysis of the results of the patient in different and complementary ways. Was the luminal tumors genomic potential has a value of Ki-67 with useful utility-based prognostic to distinguish tumors luminale and (b). Intrinsic definition subtypes of breast cancer Genomics became as the best explanation for heterogeneous results established patients. (2013) for deeper analysis of the importance of diffusion path in the behavior of intrinsic subtypes of breast cancer, we each subtype divide into two groups: with Ki-67 or 14% 14% < Ki-67. 2013 search χ. breast cancer, 15: R98 1186/bcr3559 the electronic version of this article is the most comprehensive and found on the Internet under:. ]. In this study, we examined the importance of intrinsic diffusion in behaviour of subtypes of statistical approaches several cancer breast. Applied two intrinsic definitions subtype with a group of four or six immuohistochemical brands in a number of breast cancer patients treated early in succession in a single institution. Also divide each intrinsic subtype depending on the level of the expression of Ki-67, except for subtypes luminale and luminal B, because in these cases, the expression of Ki-67 levels are down and up and by definition. We suspect that a more detailed analysis of the risk of recurrence of a methodology of the function would be able to detect differences in risk over time according to the way of distribution, even into subtypes such as triple negative rates of risk or HER2-enriched. ]. The value of Ki-67 as a prognostic indicator in other intrinsic subtypes, as triple-negative older and HER2, is unclear. Luminale population based only in our study showed significant differences in actuarial Ki CBF-67. They found no significant difference in triple negative tumors and enriched of HER2. It is possible that these results are based on the use of a threshold of Ki-67 in the luminal tumors. However, Aleskandarany and not too different thresholds defined a significant difference in survival, Actuarial Mathematics, despite the use of specially designed for triple negative tumors and HER2-enriched. ]. Information that could be patient through the study of patterns of recurrence of early breast cancer in a different way. In this sense, our results could several hypotheses are confirmed by randomized trials to generate prospective studies, would be of great practical value. First follow-up might be intrinsic format after the first treatment for any recurrence pattern expected based on void type. However, it is more important than its intrinsic adjuvant therapy can be adapted to any subtype. Patients with tumors with high prices, spread, such as HER2 or basal-like enriched, benefit from more aggressive schedules of chemotherapy (e.g. the density of dose). These types of chemotherapy that some avoid repetitions that may arise in the course of the first peak. In cases with a strong expression of car distribution, it may be useful to treat the cell cycle inhibitors with novel (for example, Palbociclib). In addition, patients with HER2 benefit subtype luminale a second treatment with Trastuzumab, to reduce the second Summit of the pattern. The strengths of our study are detailed and a reason for some breakouts for each intrinsic subtype described meticulous analysis of the BCF, as a whole, and the data are distinguished by the amount of activation of a homogeneous series distribution handled by patients, representing a broad spectrum of cancers of the breast, is not always available in clinical specimens-based studio. The main limitation of our study is able to get samples from patients with cancer. It could be argued that the use of different patterns of adjuvant chemotherapy can result in less consistency in results. Search results, the first special model of recurrence of breast cancer in the early stages described damage suggests that the structure of this model is the same, regardless of the type of adjuvant treatment used. Risk of recurrence of breast cancer varies during the recording of the time. We believe that these changes at the level of expression of the proliferation pathway and intrinsic types spend time together. ]. To improve the results obtained with the adjuvant treatment of breast cancer, it is important to develop methods to determine exactly which patients need some kind of treatment. In addition, is required, the best treatment option for each patient and the best time of treatment, because previous studies have shown, there are significant differences in the occurrence of the disease, according to the characteristics of the tumor. Using a cumulative methodology survive, researchers have found, in several studies, that triple-negative and HER2 's phenotypes that most recurrences occur, there are a considerable number of repetitions in the first 3 years of follow-up in subtypes luminale in subsequent years. ,,.